Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers
Our results support the concept that eribulin's cytotoxic effects are associated with ICD. These findings provide impetus for investigating how eribulin-induced ICD may contribute to the larger spectrum of phenotypic and immunological effects by which eribulin exerts antitumor therapeutic benefits.
Authors
- Bruce A. Littlefield
- Mingfa Zang
- Huajun Yang (ORCID: https://orcid.org/0000-0001-9888-8375)
- Bree Erickson
- Bo Li (ORCID: https://orcid.org/0000-0003-2783-9300)
- Jia Zheng (ORCID: https://orcid.org/0000-0002-5184-7514)
- Ryan C. Kunz
- Xiaoyu An (ORCID: https://orcid.org/0009-0004-5975-0727)
Institutions
- Abterra Biosciences (United States) (US)
- Crown Bioscience (China) (CN)
- Eisai (United Kingdom) (GB)
- Eisai (Japan) (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-30
- DOI
- https://doi.org/10.21873/anticanres.17391
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.88